RT Journal Article
SR Electronic
T1 Protocol for a sequential, prospective meta-analysis to describe coronavirus disease 2019 (COVID-19) in the pregnancy and postpartum periods
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.08.20228056
DO 10.1101/2020.11.08.20228056
A1 Smith, Emily R.
A1 Oakley, Erin
A1 He, Siran
A1 Zavala, Rebecca
A1 Ferguson, Kacey
A1 Miller, Lior
A1 Grandner, Gargi Wable
A1 Abejirinde, Ibukun-Oluwa Omolade
A1 Afshar, Yalda
A1 Ahmadzia, Homa
A1 Aldrovandi, Grace
A1 Akelo, Victor
A1 Tippett Barr, Beth A.
A1 Bevilacqua, Elisa
A1 Brandt, Justin S.
A1 Broutet, Natalie
A1 Fernández-Buhigas, Irene
A1 Carrillo, Jorge
A1 Clifton, Rebecca
A1 Conry, Jeanne
A1 Cosmi, Erich
A1 Delgado-López, Camille
A1 Divakar, Hema
A1 Driscoll, Amanda J.
A1 Favre, Guillaume
A1 Flaherman, Valerie
A1 Gale, Christopher
A1 Gil, Maria M.
A1 Godwin, Christine
A1 Gottlieb, Sami
A1 Bellolio, Olivia Hernandez
A1 Kara, Edna
A1 Khagayi, Sammy
A1 Kim, Caron Rahn
A1 Knight, Marian
A1 Kotloff, Karen
A1 Lanzone, Antonio
A1 Le Doare, Kirsty
A1 Lees, Christoph
A1 Litman, Ethan
A1 Lokken, Erica M.
A1 Longo, Valentina Laurita
A1 Magee, Laura A.
A1 Martinez-Portilla, Raigam Jafet
A1 McClure, Elizabeth
A1 Metz, Torri D.
A1 Money, Deborah
A1 Mullins, Edward
A1 Nachega, Jean B.
A1 Panchaud, Alice
A1 Playle, Rebecca
A1 Poon, Liona C.
A1 Raiten, Daniel
A1 Regan, Lesley
A1 Rukundo, Gordon
A1 Sanin-Blair, Jose
A1 Temmerman, Marleen
A1 Thorson, Anna
A1 Thwin, Soe Soe
A1 Tolosa, Jorge E.
A1 Townson, Julia
A1 Valencia-Prado, Miguel
A1 Visentin, Silvia
A1 von Dadelszen, Peter
A1 Waldorf, Kristina Adams
A1 Whitehead, Clare
A1 Yang, Huixia
A1 Thorlund, Kristian
A1 Tielsch, James M.
YR 2022
UL http://medrxiv.org/content/early/2022/01/04/2020.11.08.20228056.abstract
AB We urgently need answers to basic epidemiological questions regarding SARS-CoV-2 infection in pregnant and postpartum women and its effect on their newborns. While many national registries, health facilities, and research groups are collecting relevant data, we need a collaborative and methodologically rigorous approach to better combine these data and address knowledge gaps, especially those related to rare outcomes. We propose that using a sequential, prospective meta-analysis (PMA) is the best approach to generate data for policy- and practice-oriented guidelines. As the pandemic evolves, additional studies identified retrospectively by the steering committee or through living systematic reviews will be invited to participate in this PMA. Investigators can contribute to the PMA by either submitting individual patient data or running standardized code to generate aggregate data estimates. For the primary analysis, we will pool data using two-stage meta-analysis methods. The meta-analyses will be updated as additional data accrue in each contributing study and as additional studies meet study-specific time or data accrual thresholds for sharing. At the time of publication, investigators of 25 studies, including more than 76,000 pregnancies, in 41 countries had agreed to share data for this analysis. Among the included studies, 12 have a contemporaneous comparison group of pregnancies without COVID-19, and four studies include a comparison group of non-pregnant women of reproductive age with COVID-19. Protocols and updates will be maintained publicly. Results will be shared with key stakeholders, including the World Health Organization (WHO) Maternal, Newborn, Child, and Adolescent Health (MNCAH) Research Working Group. Data contributors will share results with local stakeholders. Scientific publications will be published in open-access journals on an ongoing basis.Competing Interest StatementClare Whitehead declares a a relationship with the following entities, Ferring Pharmaceuticals COVID19 Investigational, Grant, NHMRC Fellowship (salary support). Alice Panchaud declares the following research grants to institution: H2020-Grant (Consortium member of Innovative medicine initiative call 13 topic 9) (ConcePTION), Efficacy and safety studies on Medicines EMA/2017/09/PE/11, Lot 4, WP 2 lead (CONSIGN: Study on impact of COVID-19 infection and medicines in pregnancy), Safety monitoring of COVID-19 vaccines in the EU Reopening of competition no. 20 under a framework contract following procurement procedure EMA/2017/09/PE (Lot 3) 4. Federal Office of Public Health (207000 CHF). (The COVI-Preg registry). Edward Mullins declares a relationship with the following entities National Institute for Health Research (Project grant for PAN COVID study) Deborah Money declares a relationship with the following entities, Canadian Institutes of Health Research (payments to my institution only), Public Health Agency of Canada (payments to my institution only), BC Womens Foundation (payments to my institution only) and is a Member of the COVID-19 Immunity Task Force sponsored by the Canadian government. Torri D. Metz declares a relationship with the following entities, Pfizer (site Principal Investigator for SARS-CoV-2 vaccination in pregnancy study, money paid to institution and member of Medical Advisory Board for SARS-CoV-2 vaccination in pregnancy study, money paid to me), NICHD (subcommittee Chair for the NICHD Maternal-Fetal Medicine Units Network Gestational Research Assessments of COVID-19 (GRAVID) study), and Society for Maternal-Fetal Medicine (board member). Erica Lokken declares a relationship with the following entity, US NIH (paid institution). Karen L. Kotloff declares a relationship with the following entity, Bill and Melinda Gates Foundation. Siran He declares a relationship with the following entity, Bill and Melinda Gates Foundtion (payments made to my institution). Valerie Flaherman declares a relationship with the following entities, Bill and Melinda Gates Foundation (payments to my institution), Yellow Chair Foundation (payments to my institution), Robert Woods Johnson Foundation (payments to my institution), CDC Foundation, California Health Care Foundation (payments to my institution), Tara Health Foundation (payments to my institution), UCSF Womens Health Center of Excellence (payments to my institution) and California Department of Health Care Services (payments made to my institution). Jose Sanin-Blair declares a relationship with the following entity, Ferring Pharmaceuticals which give a grant ($10,000) for the expenses of RECOGEST trial and is a part of the Columbian Federation of Perinatology Yalda Afshar declares a relationship with the following entities, Bill and Melinda Gates Foundation (payments made to my institution), CDC Foundation (payments made to my institution), Robert Woods Johnson Foundation (payments made to my institution), and UCLA Deans Office COVID-19 research (payments made to my institution). Rebecca Cliffton declares a relationship with the following entity, NIH HD36801 (MFMU Network DCC).Clinical TrialPROSPERO ID: 188955Funding StatementFunded by the Bill & Melinda Gates Foundation grant to Emily Smith (INV-022057) at George Washington University and a grant to Emily Smith via a grant from the Bill & Melinda Gates Foundation to Stephanie Gaw (INV-017035) at University of California San Francisco.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This is a protocol paper and thus exempt from ethical approval. Ultimately, the meta-analysis study is exempt from human research ethics approval as the study authors will be synthesizing de-identified or aggregate data.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis is a protocol paper and there is no related data to share.